Two weekly injections, two different mechanisms, and a decision that depends on your body, your history, and your goals.
If you are weighing Wegovy against Zepbound, you are comparing two of the most widely prescribed weight management injections in the country. They work in a similar way, but they are not interchangeable. Here is how they differ and how a clinician decides which one makes sense for you.
Wegovy is semaglutide and Zepbound is tirzepatide. Both are once-weekly injections approved for chronic weight management. Tirzepatide activates two gut hormone pathways (GIP and GLP-1) while semaglutide activates one (GLP-1), and in a head-to-head trial tirzepatide produced greater average weight loss. The better choice for you still depends on tolerability, medical history, access, and cost.
What each medication is
Wegovy is the weight management brand of semaglutide, the same active ingredient found in Ozempic. Zepbound is the weight management brand of tirzepatide, the active ingredient in Mounjaro. Both are prescription medications given as a small weekly injection under the skin, and both are meant to be used alongside nutrition changes and regular movement, not instead of them.
At Just Lose Weight MD we prescribe both semaglutide and tirzepatide, so the conversation in our offices is about fit, not about pushing one product. You can read more about each on our semaglutide injections page and our tirzepatide injections page.
How they work
Semaglutide mimics GLP-1, a hormone released after eating that slows stomach emptying, signals fullness to the brain, and helps regulate blood sugar. Tirzepatide mimics GLP-1 and also GIP, a second gut hormone that appears to influence appetite, insulin response, and how the body handles fat. That dual action is the main reason tirzepatide is often described as the stronger of the two.
In daily life, both tend to make people feel full sooner, think about food less, and eat smaller portions without a constant fight against hunger.
What the research shows
In the large trials that supported approval, adults using semaglutide 2.4 mg lost roughly 15 percent of their body weight on average over about 68 weeks, while adults using the highest tirzepatide doses lost roughly 20 percent on average over 72 weeks. A later head-to-head trial comparing the two directly found greater average weight loss with tirzepatide, with figures near 20 percent versus 14 percent at 72 weeks.
Averages hide a lot of variation. Some people respond strongly to semaglutide, some respond better to tirzepatide, and some stop short of those numbers because of side effects or a lower dose ceiling. Trial participants also received lifestyle support, which is part of why results in everyday life can differ.
Dosing and schedule
Both medications start low and step up gradually to limit stomach side effects. Wegovy begins at 0.25 mg weekly and increases about every four weeks toward a 2.4 mg maintenance dose. Zepbound begins at 2.5 mg weekly and increases in 2.5 mg steps about every four weeks, with maintenance doses ranging from 5 mg up to 15 mg. Many people reach a good response at a dose below the maximum, so the goal is the lowest effective dose, not the highest one. Our guide to tirzepatide dosing walks through the usual titration.
Side effects
The side effect profiles overlap. The most common are nausea, diarrhea, constipation, vomiting, and abdominal discomfort, usually strongest after a dose increase and easing over days to weeks. Both carry a boxed warning about thyroid C-cell tumors seen in animal studies, and neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis, gallbladder problems, and dehydration are other reasons for medical oversight. Small meals and the right food choices help a great deal; see our lists of foods to avoid on Wegovy and foods to avoid on tirzepatide.
Benefits beyond the scale
Wegovy also carries an indication to reduce the risk of major cardiovascular events in adults with established heart disease who have overweight or obesity. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity. If you already have one of these conditions, that can shape the decision.
Who might lean toward which
- You have heart disease and want a medication with a cardiovascular indication: semaglutide is often discussed first.
- You have a larger weight goal or have plateaued on another medication: tirzepatide may offer more headroom.
- You are sensitive to stomach side effects: either can work, and a slower titration matters more than the brand.
- Insurance or supply decides it: the medication you can actually stay on consistently is usually the right one.
Cost and access
Coverage varies widely by plan, and both medications have had periods of limited supply. We do not quote prices in articles because they change, but our team can explain your options during a visit, in person at Takoma Park or Rockville, or through telehealth for patients in Maryland, DC, and Virginia.
Choosing with a clinician
A good decision starts with your history: past weight loss attempts, other conditions, current medications, and how you feel about weekly injections and possible side effects. Our medical weight loss program pairs the medication with nutrition guidance and follow-up so adjustments are made early. If you are ready to talk it through, you can book an appointment online or call Takoma Park at (301) 434-0075 or Rockville at (301) 603-2811.
